Trial site
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality 200123, ChinaNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 27 trials
- Phase 33 trials
- Phase 1/22 trials
- Phase 11 trial
- Status
- Active, not recruiting7 trials
- Recruiting4 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.4 trials
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 trials
- Bio-Thera Solutions1 trial
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 trial
- Ganzhou Hemay Pharmaceutical Co., Ltd1 trial
- and 4 more
Running trials
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
NCT07668154· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Yan Shi
Recruiting
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
NCT06885385· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Yong Gao, Doctor of Medicine
Recruiting
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma
NCT06781567· Phase 2· HitGen Inc.· Source
Contact: Ye Guo
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177· Phase 2· Lyvgen Biopharma Holdings Limited· Source
Active, not recruiting
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05668858· Phase 1/2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104· Phase 2· Ganzhou Hemay Pharmaceutical Co., Ltd· Source
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Ye Guo
Active, not recruiting
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897· Phase 2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error